Latest Advaxis Inc (ADXS) Headlines Biotech S
Post# of 171
Posted On: 03/08/2014 5:06:45 PM
Latest Advaxis Inc (ADXS) Headlines
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Advaxis, Inc. "Advaxis' Immunotherapy and the Tumor Microenvironment"
ACCESSWIRE - Wed Mar 05, 2:23PM CST
NEW YORK, NY / ACCESSWIRE / March 5, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the company's CEO, Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Advaxis Cancer Immunotherapy Featured on CNN
GlobeNewswire - Mon Mar 03, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy designed to treat women with breast cancer, was featured on CNN in a segment focused on its success in treating dogs with osteosarcoma (bone cancer). The segment includes an interview with Dr. Nicola Mason, Assistant Professor of Medicine and Pathobiology at the University of Pennsylvania School of Veterinary Medicine, who is the principle investigator of the featured study, funded by Advaxis, to evaluate ADXS-cHER2 in companion dogs with bone cancer.
Faruqi & Faruqi, LLP Launches An Investigation of Advaxis, Inc. For Potential Breaches of Fiduciary Duties by Its Board of Directors
PR Newswire - Fri Feb 28, 2:42PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Advaxis, Inc. ("Advaxis" or the "Company") (NasdaqCM: ADXS) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the 2011 Omnibus Incentive Plan (the "Plan").
Advaxis, Inc. - "Advaxis Immunotherapies Complement PD-1 Antibodies"
ACCESSWIRE - Tue Feb 18, 11:16AM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's CSO, Dr. Robert Petit. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day
GlobeNewswire - Tue Feb 18, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it will participate in the Canaccord Genuity Orphan Drug One-on-One Day, Monday, February 24, 2014 at the Omni Berkshire Place in New York.
Advaxis to Present at the Bloomberg 2014 State of Healthcare Summit
GlobeNewswire - Wed Feb 12, 6:45AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that Robert G. Petit, Ph.D., Chief Scientific Officer of Advaxis, will be presenting on an expert panel titled "The Future of Cancer Immunotherapy" during the Bloomberg 2014 State of Healthcare Summit on Friday, February 14, 2014 at 11:15 a.m. ET. The conference will be held at Bloomberg's offices at 731 Lexington Avenue, New York, NY 10022.
4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
SynCo Bio Partners Expands Live Microbial Product Experience
PR Newswire Europe - Tue Feb 11, 8:03AM CST
AMSTERDAM, February 11, 2014 /PRNewswire/ --
Advaxis Engages SynCo Bio Partners for Manufacturing of ADXS-HPV, Its Lead Cancer Immunotherapy Program
GlobeNewswire - Tue Feb 11, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, and SynCo Bio Partners B.V. (SynCo), one of the leading GMP contract manufacturers of biopharmaceuticals, announced today that they have signed an agreement for SynCo to manufacture Advaxis' novel drug candidate, ADXS-HPV. Under the agreement, SynCo will assist Advaxis in developing scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance and drug product. Advaxis plans to initiate registrational trials this year with ADXS-HPV for the treatment of cervical cancer.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Feb 07, 8:24AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Advaxis, Inc. - "Georgia Regents Trials"
ACCESSWIRE - Thu Feb 06, 11:13AM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's COO, Mr. Gregory T. Mayes. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Advaxis Expands Collaboration With GRU Cancer Center at Georgia Regents University to Conduct Four Cancer Immunotherapy Clinical Trials
GlobeNewswire - Wed Feb 05, 6:40AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced it has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center to conduct four Phase 1/2 clinical trials. The trials will be conducted under the supervision of Dr. Samir Khleif, Director, GRU Cancer Center and former Chief of the Vaccines Section at the National Cancer Institute (NCI).
Advaxis to Present at the BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that Daniel J. O'Connor, Chief Executive Officer of Advaxis, will be presenting a company update at the 16 Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 3:30 p.m. ET. The conference will be held at the Waldorf Astoria in New York.
Advaxis Inc. - "Incentive Programs"
ACCESSWIRE - Thu Jan 30, 1:34PM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's President and CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Advaxis, Inc. - "Key Partnerships"
ACCESSWIRE - Fri Jan 24, 11:46AM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's President and CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Biocon Collaborates with Advaxis for 'ADXS-HPV' A Novel Cancer Immunotherapy
Business Wire - Wed Jan 22, 8:30AM CST
Biocon Ltd., (BIOCON.BO), Asia's premier biotechnology company, and Advaxis, Inc., (NASDAQ: ADXS), a leader in developing the next generation of cancer immunotherapies, announced today that they have entered into an exclusive licensing agreement for co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)-associated cervical cancer in women, for India and key emerging markets.
Covidien Completes Confluent Surgical Sale - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 3:00PM CST
The Confluent Surgical product line comprises soft tissue repair division of COV's Medical Devices segment
Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study
Business Wire - Tue Jan 21, 6:30AM CST
Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery (TORS) to remove their tumors. HPV-associated head and neck cancer is the most rapidly growing form of head and neck cancer, and is caused by the same virus that causes cervical cancer.
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Advaxis, Inc. "Advaxis' Immunotherapy and the Tumor Microenvironment"
ACCESSWIRE - Wed Mar 05, 2:23PM CST
NEW YORK, NY / ACCESSWIRE / March 5, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the company's CEO, Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Advaxis Cancer Immunotherapy Featured on CNN
GlobeNewswire - Mon Mar 03, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy designed to treat women with breast cancer, was featured on CNN in a segment focused on its success in treating dogs with osteosarcoma (bone cancer). The segment includes an interview with Dr. Nicola Mason, Assistant Professor of Medicine and Pathobiology at the University of Pennsylvania School of Veterinary Medicine, who is the principle investigator of the featured study, funded by Advaxis, to evaluate ADXS-cHER2 in companion dogs with bone cancer.
Faruqi & Faruqi, LLP Launches An Investigation of Advaxis, Inc. For Potential Breaches of Fiduciary Duties by Its Board of Directors
PR Newswire - Fri Feb 28, 2:42PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Advaxis, Inc. ("Advaxis" or the "Company") (NasdaqCM: ADXS) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the 2011 Omnibus Incentive Plan (the "Plan").
Advaxis, Inc. - "Advaxis Immunotherapies Complement PD-1 Antibodies"
ACCESSWIRE - Tue Feb 18, 11:16AM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's CSO, Dr. Robert Petit. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day
GlobeNewswire - Tue Feb 18, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it will participate in the Canaccord Genuity Orphan Drug One-on-One Day, Monday, February 24, 2014 at the Omni Berkshire Place in New York.
Advaxis to Present at the Bloomberg 2014 State of Healthcare Summit
GlobeNewswire - Wed Feb 12, 6:45AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that Robert G. Petit, Ph.D., Chief Scientific Officer of Advaxis, will be presenting on an expert panel titled "The Future of Cancer Immunotherapy" during the Bloomberg 2014 State of Healthcare Summit on Friday, February 14, 2014 at 11:15 a.m. ET. The conference will be held at Bloomberg's offices at 731 Lexington Avenue, New York, NY 10022.
4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
SynCo Bio Partners Expands Live Microbial Product Experience
PR Newswire Europe - Tue Feb 11, 8:03AM CST
AMSTERDAM, February 11, 2014 /PRNewswire/ --
Advaxis Engages SynCo Bio Partners for Manufacturing of ADXS-HPV, Its Lead Cancer Immunotherapy Program
GlobeNewswire - Tue Feb 11, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, and SynCo Bio Partners B.V. (SynCo), one of the leading GMP contract manufacturers of biopharmaceuticals, announced today that they have signed an agreement for SynCo to manufacture Advaxis' novel drug candidate, ADXS-HPV. Under the agreement, SynCo will assist Advaxis in developing scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance and drug product. Advaxis plans to initiate registrational trials this year with ADXS-HPV for the treatment of cervical cancer.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Feb 07, 8:24AM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
Advaxis, Inc. - "Georgia Regents Trials"
ACCESSWIRE - Thu Feb 06, 11:13AM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's COO, Mr. Gregory T. Mayes. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Advaxis Expands Collaboration With GRU Cancer Center at Georgia Regents University to Conduct Four Cancer Immunotherapy Clinical Trials
GlobeNewswire - Wed Feb 05, 6:40AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced it has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center to conduct four Phase 1/2 clinical trials. The trials will be conducted under the supervision of Dr. Samir Khleif, Director, GRU Cancer Center and former Chief of the Vaccines Section at the National Cancer Institute (NCI).
Advaxis to Present at the BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that Daniel J. O'Connor, Chief Executive Officer of Advaxis, will be presenting a company update at the 16 Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 3:30 p.m. ET. The conference will be held at the Waldorf Astoria in New York.
Advaxis Inc. - "Incentive Programs"
ACCESSWIRE - Thu Jan 30, 1:34PM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's President and CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Advaxis, Inc. - "Key Partnerships"
ACCESSWIRE - Fri Jan 24, 11:46AM CST
Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman's Blog, written by the company's President and CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Biocon Collaborates with Advaxis for 'ADXS-HPV' A Novel Cancer Immunotherapy
Business Wire - Wed Jan 22, 8:30AM CST
Biocon Ltd., (BIOCON.BO), Asia's premier biotechnology company, and Advaxis, Inc., (NASDAQ: ADXS), a leader in developing the next generation of cancer immunotherapies, announced today that they have entered into an exclusive licensing agreement for co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)-associated cervical cancer in women, for India and key emerging markets.
Covidien Completes Confluent Surgical Sale - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 3:00PM CST
The Confluent Surgical product line comprises soft tissue repair division of COV's Medical Devices segment
Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study
Business Wire - Tue Jan 21, 6:30AM CST
Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery (TORS) to remove their tumors. HPV-associated head and neck cancer is the most rapidly growing form of head and neck cancer, and is caused by the same virus that causes cervical cancer.
(0)
(0)Advaxis Inc. (ADXS) Stock Research Links
Scroll down for more posts ▼